Ultragenyx Pharmaceutical (RARE) Share-based Compensation Growth (5y) (2018 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Ultragenyx Pharmaceutical | 2.29 Bn | 1.89 Bn | 106.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -73.80% |
| Dec 31, 2025 | 10.41% |
| Sep 30, 2025 | 12.72% |
| Jun 30, 2025 | 11.50% |
| Mar 31, 2025 | -71.19% |
| Dec 31, 2024 | 15.34% |
| Sep 30, 2024 | 15.87% |
| Jun 30, 2024 | 12.13% |
| Mar 31, 2024 | 12.80% |
| Dec 31, 2023 | 9.72% |
| Sep 30, 2023 | 11.03% |
| Jun 30, 2023 | 12.11% |
| Mar 31, 2023 | 11.19% |
| Dec 31, 2022 | 8.48% |
| Sep 30, 2022 | 15.79% |
| Jun 30, 2022 | 16.39% |
| Mar 31, 2022 | 15.18% |
| Dec 31, 2021 | 14.65% |
| Sep 30, 2021 | 14.53% |
| Jun 30, 2021 | 20.11% |
| Mar 31, 2021 | 18.92% |
| Dec 31, 2020 | 19.20% |
| Sep 30, 2020 | 20.84% |
| Jun 30, 2020 | 34.50% |
| Mar 31, 2020 | 52.95% |
| Dec 31, 2019 | 57.93% |
| Sep 30, 2019 | 64.51% |
| Jun 30, 2019 | 87.98% |
| Mar 31, 2019 | 91.02% |
| Dec 31, 2018 | 151.38% |
| Sep 30, 2018 | 211.03% |
| Jun 30, 2018 | 154.01% |
| Mar 31, 2018 | 150.39% |